In this issue, we share exciting developments in ITP presented at this year's 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, December 7-10, 2024. First, PDSA staff and members of the Pediatric ITP Consortium of North America (ICON) collaborated on research using data from our ITP Natural History Study Registry. Second, PDSA Medical Advisor, David Kuter, MD, highlights results from the LUNA clinical trial for a new drug on the horizon to treat adults and adolescents with ITP, called rilzabrutinib.
CONTENTS:
CONTENTS:
In this issue of the e-news, we want to share with you the preliminary results of a research study that was presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego, California, December 9-12, 2023, and involved PDSA staff and many of our medical advisors, in addition to several of PDSA’s patient members representing the voice of the ITP patient. This work was led by Donald Arnold, MD, one of PDSA’s medical advisors and his research associate Emily Sirotich.
CONTENTS: